Zydus Lifesciences

Hitesh Rathi of Angel One recommends adopting a buy on dips approach for the Nifty, with prior resistance zone of 24,180-24,100 now likely to act as an immediate support cluster.

The joint venture will invest over $20 million in a pharmaceutical manufacturing facility in Sri Lanka to boost local drug production and reduce reliance on imports

Zydus Lifesciences and Sri Lanka's Sunshine Healthcare on Friday announced the setting up of a joint venture with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in the island nation. The company has entered into a share subscription and shareholders' agreement (SSSHA) with Sunshine Healthcare Lanka Ltd (Sunshine) and Zydus Sunshine Lifesciences (Pvt) Ltd (Zydus Sunshine), Zydus Lifesciences said in a regulatory filing. Under the SSSHA, Zydus Lifesciences will subscribe 50 per cent of the total paid-up equity share capital of Zydus Sunshine for up to USD 5 million in one or more tranches, it added. Zydus Sunshine will set up a manufacturing facility in Horana Export Processing Zone in Sri Lanka to manufacture pharmaceutical products, which will strengthen local production and reduce import dependence, the filing said. This will improve access to high-quality medicines while supporting national supply chain resilience, it ...

Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27

The pharmaceutical company said the buyback price has been increased from ₹1,150 per equity share to ₹1,260 per equity share

The US FDA has granted priority review to Saroglitazar, Zydus Lifesciences' drug for treating Primary Biliary Cholangitis

In the March quarter (Q4FY26), Zydus Lifesciences reported a net profit of ₹1,272.5 crore, as compared to ₹1,170.9 crore a year ago, up 8.7 per cent

Zydus Lifesciences reported strong fourth-quarter earnings growth, supported by robust performance in India, international markets, and consumer wellness

Q4FY26 company results: Firms including Zydus Lifesciences, BASF India, PI Industries, Zee Entertainment, and Bosch Home Comfort India are also to release their January-March earnings today

Zydus Wellness Ltd on Monday reported 5.75 per cent decline in consolidated net profit at Rs 162 crore for the fourth quarter ended March 31, 2026 impacted by higher expenses and taxes. The company had posted a net profit of Rs 171.9 crore for the year-ago period, Zydus Wellness said in a regulatory filing. Total revenue from operations in the fourth quarter stood at Rs 1,484.7 crore as compared to Rs 913.1 crore in the year-ago period. Total expenses were at Rs 1,308.6 crore as against Rs 740.5 crore. Total tax expenses were also higher at Rs 15.3 crore as compared to Rs 1.5 crore in March quarter FY25. In FY26, the consolidated net profit was at Rs 197.2 crore as compared to Rs 346.9 crore a year ago. Total revenue from operations stood at Rs 3,961 crore as against Rs 2,708.9 crore. The board of directors at its meeting held on May 18, 2026 recommended a final dividend of Rs 1.20 per equity share of Rs 2 each, subject to approval of the shareholders.

The buying on the counter came after the company, through a filing, said that its board will consider a buyback in a meeting along with the financial results on Tuesday, May 19, 2026

Acquisition gives Zydus a branded-drugs commercial platform in the US and strengthens its specialty pharmaceutical presence in pain and oncology therapies

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite

Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its drug Desidustat tablets used for treating renal anaemia. The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd. CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, had obtained an exclusive license for the drug from Zydus in 2020. Desidustat tablets are administered orally for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure. "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally," Zydus Lifesciences MD Sharvil P Patel said in a statement. The company is happy to partner with CMS and is confident that th

The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions ​of the agreement are confidential

Apex court declines to halt Zydus' biosimilar nivolumab launch, asks Bristol Myers Squibb to seek interim relief before Delhi High Court

Zydus Lifesciences posted higher Q3 profit and revenue, aided by strong growth in the US and India businesses, improved margins, and steady momentum in generics, specialty and chronic segments

Zydus Life Q3 Ebitda for the quarter was ₹1,816.4 crore, up 31 per cent Y-o-Y. Ebitda margin during the same period stood at 26.5 per cent, marking an improvement of 20 basis points